Cosentyx is a prescription drug used to treat certain autoimmune diseases, such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. According to the drug's official website, Cosentyx is approved for use in patients aged 6 years and older with moderate to severe plaque psoriasis [3]. However, the appropriate age for Cosentyx treatment may vary depending on the specific condition being treated and the patient's individual health needs.

The drug's safety and efficacy have been evaluated in clinical trials involving adult patients, and some studies have included adolescent patients [2]. According to Drug Patent Watch, Cosentyx was approved by the FDA in 2015 for the treatment of plaque psoriasis in adults [1]. The drug's prescribing information states that the safety and effectiveness of Cosentyx have not been established in pediatric patients with psoriatic arthritis or ankylosing spondylitis [2].

Therefore, it is important for patients and their healthcare providers to carefully consider the risks and benefits of Cosentyx treatment based on the patient's age, medical history, and specific condition being treated. The decision to use Cosentyx in pediatric patients should be made on a case-by-case basis, taking into account the potential risks and benefits of the drug [2].

In conclusion, Cosentyx is approved for use in patients aged 6 years and older with moderate to severe plaque psoriasis. However, the appropriate age for Cosentyx treatment may vary depending on the specific condition being treated and the patient's individual health needs. The decision to use Cosentyx in pediatric patients should be made on a case-by-case basis, taking into account the potential risks and benefits of the drug.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf
[3] https://www.cosentyx.com/